PF-07799933 + binimetinib

PF-07799933 + binimetinib is a combination therapy under clinical investigation for advanced solid tumors with BRAF mutations. PF-07799933 is an oral, selective, ATP-competitive small molecule RAF kinase inhibitor targeting BRAF signaling in both BRAF V600-mutant and non-V600-mutant tumors. It is distinct in sparing non-mutated RAF dimers, reducing paradoxical MAPK pathway activation compared to first-generation BRAF inhibitors. Binimetinib is a selective, oral MEK inhibitor. The combination is aimed at overcoming acquired resistance mechanisms in BRAF-mutant cancers and enhancing anti-tumor responses, including in tumors refractory to prior BRAF or MEK inhibitor therapy. The therapy is being tested particularly in patients with various classes of BRAF-mutated malignancies, including those with brain involvement[1][2][3].

Other names

ARRY-439162ARRY439162ARRY 439162